Beyfortus (nirsevimab), a single-dose monoclonal antibody developed and commercialized in partnership by AstraZeneca (NASDAQ:AZN) and Sanofi (NASDAQ:SNY), has been approved in Japan for the prevention...
Source LinkBeyfortus (nirsevimab), a single-dose monoclonal antibody developed and commercialized in partnership by AstraZeneca (NASDAQ:AZN) and Sanofi (NASDAQ:SNY), has been approved in Japan for the prevention...
Source Link
Comments